🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Fulgent Genetics, Inc. FLGT R2KR3KPHARMA

Healthcare · Diagnostics & Research · United States
https://www.fulgentgenetics.com
Company Profile ↓
$20.10
-7.67% 1Y
Mkt Cap$553.06M
P/E-7.13
P/B0.60
52W High$30.85
52W Low$13.79
Book Value$36.40
EPS (TTM)$-2.82

Company Overview

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 65.3% CAGR over the past five years.

Recent Developments

  • Dec 2025 Revenue of $322.67M (+13.8% YoY); net profit $-60.51M.
  • Trailing 12 Months Year-on-year growth — revenue +4.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 65.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:65.34%
1 Year:4.40%

Stock Price Performance

1 Year:-7.67%
6 Months:+23.24%
3 Months:+2.66%
1 Month:-6.73%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 37% of range
$13.79 $30.85
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)43.75 · Neutral
Price Performance
1M-6.73%
3M+2.66%
6M+23.24%
1Y-7.67%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 65.3% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 34.9% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-7.13
Industry PE
25.45
Forward P/E
-14.57
PEG Ratio
-
Book Value
$36.40
Price to Book
0.60
P/S
1.85
EV/EBITDA
-3.50
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
65.34%
Profit 5Y
-
Revenue (YoY)
4.40%
Earnings (YoY)
-

Profitability & Returns

ROCE
-8.07%
ROE
-8.11%
ROA
-6.30%
Profit Margin
-26.05%
Op Margin
-39.35%
Gross Margin
35.58%
EPS (Latest Qtr)
$-0.11
EPS (TTM)
$-2.82

Balance Sheet & Liquidity

Debt/Equity
0.96
Quick Ratio
4.57
Current Ratio
6.34
Debt
$9.60M
Total Assets
$1.09B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
37.75%
Chg in Prom Hold
-0.06%
FII / Inst Holding
58.40%
Chg in FII Hold
-0.15%

Financial Snapshot

Enterprise Value
$553.06M
Total Revenue (TTM)
$323.93M
EBITDA
$-89.46M
Free Cash Flow
$-90.90M
Operating Cash Flow
$-83.70M
Shares Outstanding
27.52M
Gross Margin
35.58%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 FLGT Fulgent Genetics, Inc. R2KR3KPHARMA 20.10 -7.13 $553.06M 0.00% -8.07% -8.11% 65.34% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue -----5.31M4.64M4.50M4.28M4.65M5.40M5.62M5.67M5.37M8.42M10.35M8.39M7.75M17.27M101.72M294.98M359.43M153.62M227.87M251.67M320.27M125.34M105.66M67.70M66.17M67.85M84.69M64.48M71.03M71.74M73.46M81.80M84.07M71.14M85.39M
Gross Profit 175.00K2.14M2.56M2.87M3.99M3.45M2.76M2.23M1.74M1.88M2.86M3.01M2.90M2.40M4.80M6.46M4.75M3.70M9.55M75.45M243.21M285.35M117.76M184.40M189.54M242.54M65.28M46.09M12.99M18.81M20.57M39.84M22.10M26.49M26.77M28.35M34.44M35.51M21.49M25.68M
Operating Income -7.34M-615.00K970.00K-695.00K1.26M219.00K-150.00K-1.48M-2.07M-2.19M-1.00M-846.00K-1.03M-1.82M295.00K1.51M-409.00K-1.91M2.64M63.52M225.91M266.92M98.90M159.27M150.86M201.93M12.79M352.00K-36.55M-24.82M-19.80M214.00K-21.80M-18.91M-17.08M-19.80M-19.71M-15.35M-34.62M-36.07M
Net Income -7.34M-602.00K-4.49M-1.11M813.00K232.00K-25.00K-1.09M-1.62M-1.91M-1.05M-595.00K-2.05M-1.91M331.00K1.46M-296.00K-1.96M3.32M46.64M166.31M200.69M79.81M122.52M104.34M153.98M11.54M1.72M-23.83M-15.34M-11.23M-13.11M-13.46M-8.71M-14.65M-11.53M-18.96M-6.61M-24.83M-29.53M
Diluted EPS -0.61-0.02-5.49-0.440.050.010.00-0.06-0.09-0.11-0.06-0.03-0.11---------------------------
R&D Expense 3.65M561.00K656.00K1.52M818.00K851.00K920.00K1.13M1.32M1.46M1.21M1.44M1.43M1.42M1.57M1.74M1.79M1.98M1.85M3.18M4.58M5.42M5.31M6.02M7.46M5.99M6.91M7.51M8.51M9.78M9.69M10.01M11.43M13.49M11.78M12.39M13.48M13.86M14.18M14.55M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.28M9.58M18.28M18.73M21.35M32.53M421.71M992.58M618.97M289.21M283.47M322.67M
Gross Profit 342.00K4.51M11.55M10.18M10.65M18.42M331.90M777.05M366.90M104.46M107.22M130.88M
Operating Income -990.00K-5.01M918.00K-3.48M-5.07M-428.00K290.16M675.95M178.53M-195.53M-73.92M-91.10M
Net Income -4.28M-8.31M-5.35M-2.51M-5.61M-411.00K214.31M507.36M143.40M-167.82M-42.71M-60.51M
R&D Expense 521.00K4.43M3.56M4.22M5.53M6.54M11.58M24.22M28.91M41.44M48.82M53.91M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --5.83M58.04M57.18M53.90M88.76M700.46M1.28B1.39B1.24B1.22B1.21B
Total Equity 1.97M1.68M5.15M54.48M54.18M51.15M82.78M569.39M1.16B1.27B1.14B1.13B1.11B
Cash & Equivalents --489.00K7.90M6.49M6.74M11.96M87.43M164.89M79.51M97.47M55.14M50.19M
Total Liabilities --686.00K3.56M3.01M2.75M5.98M131.07M112.84M116.18M102.04M90.81M106.81M
Current Liabilities --686.00K3.32M3.00M2.74M3.72M130.12M105.31M88.11M73.02M72.90M84.97M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -4.40M-969.00K4.41M1.33M-675.00K5.52M140.63M538.58M253.52M27.00M21.06M-101.64M
Investing Cash Flow -780.00K-2.21M-42.80M-2.05M950.00K-29.05M-326.44M-546.55M-261.31M38.90M-58.35M111.37M
Financing Cash Flow 4.00M3.50M45.79M-770.00K15.00K28.77M261.25M85.41M-77.14M-47.78M-4.85M-14.79M
Capital Expenditure -731.00K-2.10M-3.79M-2.90M-2.32M-1.18M-35.13M-23.81M-18.77M-22.21M-40.31M-22.57M
Free Cash Flow -5.13M-3.07M617.00K-1.56M-3.00M4.33M105.50M514.76M234.75M4.80M-19.25M-124.21M
Share Buybacks -----21.00K62.00K-74.34M25.06M225.00K10.88M

Ratios (Annual)

Figures in %.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 26.8%47.1%63.2%54.3%49.9%56.6%78.7%78.3%59.3%36.1%37.8%40.6%
Operating Margin % -77.5%-52.3%5.0%-18.6%-23.7%-1.3%68.8%68.1%28.8%-67.6%-26.1%-28.2%
Net Margin % -335.1%-86.8%-29.3%-13.4%-26.3%-1.3%50.8%51.1%23.2%-58.0%-15.1%-18.8%
ROE % -254.3%-161.6%-9.8%-4.6%-11.0%-0.5%37.6%43.8%11.3%-14.8%-3.8%-5.4%
ROCE % --97.4%1.7%-6.4%-9.9%-0.5%50.9%57.6%13.8%-16.8%-6.4%-8.1%

Shareholding Pattern

Insiders
37.75%
Institutions
58.40%
Public Float
93.82%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.31% 2.29M $49.71M
2 Acadian Asset Management. LLC 3.70% 1.02M $22.13M
3 Vanguard Capital Management LLC 2.87% 789.50K $17.16M
4 Jacobs Levy Equity Management, Inc. 2.84% 782.12K $17.00M
5 JPMORGAN CHASE & CO 2.75% 756.56K $16.45M
6 Diametric Capital, Lp 2.54% 697.78K $15.17M
7 Ameriprise Financial, Inc. 2.44% 670.08K $14.57M
8 Dimensional Fund Advisors LP 2.27% 625.36K $13.60M
9 Geode Capital Management, LLC 1.89% 521.01K $11.33M
10 State Street Corporation 1.81% 498.67K $10.84M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FLGT

Google News Fri, 23 Oct 2026

Fulgent Genetics (NASDAQ:FLGT) Stock Breaks Below 50 Day Moving Average - Here's Why - MarketBeat

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOTVN4cWxhdmlXRlZ3ZFBaYmdBVS1jOEY4NVRlYWxpRWxWYmdqSUp1OG80Y2ZZX29NdXVab09SSGFyWGdOY0dJVGhrdVdYZjYtQUN4cWl1eUF5ZmJlTkt4VVhVZVNhbU5kU0o4QjBtYzJTUXY2VkZ3elR6anVzQUwxenQ5dGhjeTNhOVhWVj…

Google News hu, 25 Jun 2026

Fulgent Genetics (FLGT) Stock Faces Mixed Analyst Target Changes After Margin Questions - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNRGx5cmpZR1hWaHdZdFE2b29jLUtReVVPUjRhYXUwa29Hd1pWbXZ1cTE3VWVZaGtvR1ZmRTNCbk1QWlBBcVNkNVhxeFRqMUhsbEZESnVEZ1JIMWJCRzVoWnNnbXRKOVhCalZjMkxyRG1mZ29wMXVaQ01fRjRlc1NjS2RYalEzRE82bWNxZU…

Google News Mon, 13 Jul 2026

Fulgent Genetics: Strong Moves By Management Keep Me Bullish (NASDAQ:FLGT) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOVFFSUVY5ekd6cnFZMnl5UUVjeWdRdmthemdJWHJqSnMzV0RLNVI4YW5oQWdUYVJmQ2NpdHFmUTUwY1lmRHMxRjZMMU91bGVlN01FR1cyc3hMUzkxXzdXUmFXcF9vZFpoZFpHQlJoOHhoZkdDa2F0NEJqTEs4LUV3NWh3VTJnbW81dlFlMz…

Google News hu, 22 Oct 2026

Understanding Momentum Shifts in (FLGT) - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQYjZZaFBjU3JWQTFkeEljbEJHaFdvamhiSUFPRHFPdXFBc0pxUkRlejdMWDFNcVozc0RaVUtwN1hzOGlUQ1laR05seklTNmRyRTV3NnY2cHMtQUlES1p2b3R2ZTlRdUNEUGU1eHJFS3lNcktZX3RIOGlUdXFzT3d2M3NHMjA3RzhfaTVzOE…

Google News Fri, 26 Jun 2026

FLGT Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBfamJYLURkenZvRDFRNWVMeTI2V1NYcVRqQW82WERIc01lX1JPY0VacGc3UVVKNzNPT0paS2JFUTdCTXdzanByck9heVhfekU2ZE5qcFZ3SzlWa0h4MnZrWmVRY2tzZUVyWVNWa25zUFprNThiRkt5TmtR?oc=5" target="_blank">FLG…

Google News ue, 26 May 2026

FLGT - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1XeU1JWkwtRFlnSXFNbl9TVG5YS0xBZjFmdHRCZlQ1d1VlTXk4S1VJNV9Ga1FWUElCcGxHblF6TEtIa00zY1E?oc=5" target="_blank">FLGT</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

FLGT — Frequently Asked Questions

What is the current share price of Fulgent Genetics, Inc. (FLGT)?

As of 2026-10-23 16:27 PDT, Fulgent Genetics, Inc. (FLGT) trades at $20.10 on NasdaqGM. Its 52-week range is $13.79 to $30.85.

What is the market capitalisation of FLGT?

Fulgent Genetics, Inc. (FLGT) has a market capitalisation of $553.06M on NasdaqGM.

What is the P/E ratio of FLGT?

FLGT trades at a trailing price-to-earnings (P/E) ratio of -7.13. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 0.60.

What is the return on equity (ROE) of FLGT?

FLGT has a return on equity (ROE) of -8.11%. Its return on capital employed (ROCE) is -8.07%.

Is FLGT a good stock to buy?

This page provides a data-driven analysis of Fulgent Genetics, Inc. (FLGT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space